Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® Elacestrant for Patients with ER+ HER2- Advanced or Metastatic Breast Cancer mBC

FLORENCE, Italy and NEW YORK, Nov. 26, 2024 /PRNewswire/

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to Cancer Patients, will present new and Expanded Data on ORSERDU® (Elacestrant) at the upcoming 2024 San Antonio Breast Cancer Symposium (SABCS), December 10-13, 2024. Of note, the company will bring real-world progression-free survival (rwPFS) results of ORSERDU in adult Patients with ER+/HER2-, Advanced or Metastatic Breast Cancer (mBC). Additionally, the company will present updated efficacy results of Elacestrant plus abemaciclib, along with a pooled safety analysis from phase 1b/2 of both the ELECTRA and ELEVATE trials.Leggi su Liberoquotidiano.it